glp-1 drugs and crohn's disease SAFETY CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL PATIENTS GLP-1 Use in Crohn's Disease:
Description
The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)
The surprising science and sobering risks revealed.
The PatchAid Berberine Patch delivers a plant-based formula straight through your skin
sales of GLP-1 drugs were $13.7 billion.
They won't get the real medication in "GLP-1 patches," doctors warn.
